Trial Profile
A Phase III, Equivalence Clinical Trial to Investigate the Efficacy and Safety of a Single Injection of 100 microg Org 36286 (Corifollitropin Alfa) to Induce Multifollicular Development for Ovarian Stimulation Using Daily Recombinant FSH as Reference
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 May 2022
Price :
$35
*
At a glance
- Drugs Corifollitropin alfa (Primary) ; Chorionic gonadotropin; Follicle stimulating hormones; Follitropin beta; Ganirelix; Progesterone; Progesterone
- Indications Female infertility
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms ENSURE
- Sponsors Organon; Schering-Plough
- 17 Jun 2019 This trial has been completed in France, according to European Clinical Trials Database.
- 03 Jul 2012 Additional location (Denmark) added as reported by European Clinical Trials Database.(Parent trial: EudraCT2006-003811-36).
- 01 Jul 2009 Results have been presented at the European Society of Human Reproduction and Embryology, according to a Schering-Plough media release.